Lanean...
Venetoclax for AML: changing the treatment paradigm
Venetoclax is a specific B-cell lymphoma-2 (BCL-2) inhibitor that can restore activation of apoptosis in malignancies, the survival of which depends on dysregulation of this pathway. Preclinical data, using various model systems including cell lines and patient samples, suggested targeting BCL-2 cou...
Gorde:
| Argitaratua izan da: | Blood Adv |
|---|---|
| Egile Nagusiak: | , , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
American Society of Hematology
2019
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6929394/ https://ncbi.nlm.nih.gov/pubmed/31869416 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2019000937 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|